Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
Sigilon Therapeutics, a biotechnology company listed on NASDAQ under the symbol SGTX, announced that its CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Needham Virtual Healthcare Conference on April 20, 2023, at 10:15 a.m. EDT. The presentation will be available via a webcast on the company’s investor website, with a replay accessible for 90 days post-event.
Sigilon is focused on developing functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, utilizing engineered cell-based therapies encapsulated in Afibromer™ biomaterials to prevent immune rejection. The company aims to address various diseases, including diabetes, by providing therapeutic solutions that are currently lacking in patients.
- None.
- None.
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference. The presentation will take place on Thursday, April 20, 2023 at 10:15 a.m. EDT.
A webcast of the presentation will be accessible through the investor section of the company’s website at www.sigilon.com, with a replay available for 90 days following the event.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of acute and chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce a wide range of functions or therapeutic molecules that may be missing or deficient in patients living with diseases such as diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Investor Contact
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837
Media Contact
Amy Bonanno
Solebury Strategic Communications
abonanno@soleburystrat.com
914-450-0349
FAQ
What is the date and time of Sigilon Therapeutics' presentation at the Needham Conference?
How can I access the webcast of Sigilon Therapeutics' presentation?
What is Sigilon Therapeutics' focus in biotechnology?
What technologies does Sigilon Therapeutics use in its therapies?
